Related Experiment Videos
Phosphodiesterase 5 inhibitors for erectile dysfunction.
Stephen M Setter1, Jason L Iltz, Jack E Fincham
1Department of Pharmacotherapy, College of Pharmacy, Washington State University/Elder Services, Spokane, WA 99217-6131, USA. ssetter@smhca.org
The Annals of Pharmacotherapy
|June 9, 2005
Summary
Phosphodiesterase 5 (PDE5) inhibitors, including sildenafil, vardenafil, and tadalafil, are safe and effective treatments for erectile dysfunction (ED). These medications offer similar efficacy and safety profiles for men experiencing ED due to various causes.
Area of Science:
- Pharmacology
- Urology
- Clinical Medicine
Background:
- Erectile dysfunction (ED) is a prevalent condition in males, with incidence increasing with age.
- Cardiovascular disease, prostatectomy, and diabetes mellitus are associated with a higher prevalence of ED.
Purpose of the Study:
- To review pharmacologic and clinical trial data for FDA-approved phosphodiesterase 5 (PDE5) inhibitors.
- Evaluate PDE5 inhibitors for the treatment of erectile dysfunction (ED).
Main Methods:
- Searched ScienceDirect, PubMed/MEDLINE, and International Pharmaceutical Abstracts (1990-2004).
- Utilized keywords: PDE5 inhibitor, erectile dysfunction, sildenafil, vardenafil, tadalafil, prostatectomy, diabetes.
- Consulted package inserts for sildenafil, vardenafil, and tadalafil.
Main Results:
- Sildenafil, vardenafil, and tadalafil are selective PDE5 inhibitors for ED treatment.
- These drugs exhibit slight variations in pharmacology and pharmacokinetics, potentially affecting duration of action.
- All agents demonstrated similar clinical efficacy and adverse effect profiles across diverse ED patient populations.
Conclusions:
- Sildenafil, vardenafil, and tadalafil are confirmed as safe and effective PDE5 inhibitors.
- These medications represent a viable therapeutic option for managing erectile dysfunction.